Predicting the Blood-Brain Barrier Permeability of New Drug-Like Compounds via HPLC with Various Stationary Phases

Małgorzata Janicka 1, Małgorzata Sztanke 2,* and Krzysztof Sztanke 3,*

1 Department of Physical Chemistry, Faculty of Chemistry, Institute of Chemical Science, Maria Curie-Skłodowska University, Maria Curie-Skłodowska Sq. 3, 20-031 Lublin, Poland; malgorzata.janicka@poczta.umcs.lublin.pl
2 Chair and Department of Medical Chemistry, Medical University, 4A Chodżki Street, 20-093 Lublin, Poland
3 Laboratory of Bioorganic Synthesis and Analysis, Chair and Department of Medical Chemistry, Medical University, 4A Chodżki Street, 20-093 Lublin, Poland
* Correspondence: malgorzata.sztanke@umlub.pl (M.S.); krzysztof.sztanke@umlub.pl (K.S.);
Tel.: +48-814486195 (M.S. & K.S.)

Received: 23 November 2019; Accepted: 21 January 2020; Published: 23 January 2020

Abstract: The permeation of the blood-brain barrier is a very important consideration for new drug candidate molecules. In this research, the reversed-phase liquid chromatography with different columns (Purosphere RP-18e, IAM.PC.DD2 and Cosmosil Cholesterol) was used to predict the penetration of the blood-brain barrier by 65 newly-synthesized drug-like compounds. The linear free energy relationships (LFERs) model (log BB = c + eE + sS + aA + bB + vV) was established for a training set of 23 congeneric biologically active azole compounds with known experimental log BB (BB = Cblood/Cbrain) values (R² = 0.9039). The reliability and predictive potency of the model were confirmed by leave-one-out cross validation as well as leave-50%-out cross validation. Multiple linear regression (MLR) was used to develop the quantitative structure-activity relationships (QSARs) to predict the log BB values of compounds that were tested, taking into account the chromatographic lipophilicity (log k_w), polarizability and topological polar surface area. The excellent statistics of the developed MLR equations (R² > 0.8 for all columns) showed that it is possible to use the HPLC technique and retention data to produce reliable blood-brain barrier permeability models and to predict the log BB values of our pharmaceutically important molecules.

Keywords: HPLC; blood-brain barrier permeability; IAM column; Cholesterol column; ODS column; QSARs; LFERs

1. Introduction

The biological activity of drugs depends primarily on their pharmacokinetics. The expected pharmacological effect of a given drug can be observed if the pharmacokinetic processes provide its high concentration within the range of the receptor. The amount of drug in tissue and the time that remains an effective concentration depend on the fundamental processes that make up the pharmacokinetic phase of the drug’s action, i.e., liberation (L), absorption (A), distribution (D), metabolism (M) and excretion (E). It is extremely difficult to predict the processes mentioned above because all of them are concentration-dependent and connected with the chemical structure of the agent. Since most drugs must pass through at least one cell membrane to provide the desired effect, for the rational design of drugs, it is vitally important to understand and to be able to predict the solute partitioning in the biomembranes. Drugs can cross membranes by passive or active transport [1–3]. While active transport is determined by compounds’ affinities for specific transporters and it uses energy, the most
common mode for the passage of xenobiotics is passive transport, which depends on physicochemical properties of the compound, such as lipophilicity, size of the molecule, ionization state, as well as the diffusion coefficient through the membrane and the concentration gradient of the compound [4,5].

One of the most important properties of a potential drug is the ability of its molecule to penetrate the blood-brain barrier (BBB). Potential effective agents that are intended to interact with the central nervous system must be able to cross the BBB and satisfactory transport through the blood-brain barrier is an essential prerequisite for a potential drug to affect the central nervous system. However, the agents that act peripherally should not cross the BBB in order to avoid side effects. In both cases, the permeability of the BBB must be known and it should be evaluated at the earliest possible stage of testing. Doing so allows scientists to choose drug candidates that have more selective pharmacologic properties with fewer side effects and lower toxicities [6].

The common measure of the extent permeation of the blood-brain barrier is the ratio of the concentration of the drug in the brain (Cbrain) to the concentration of the drug in the blood (Cblood) or in the plasma (Cplasma), which is expressed as the log BB (BB = Cblood/Cbrain) [7–9]. Although measurement of the blood-brain barrier penetration in vivo is essential, the procedure is time-consuming, expensive and difficult. In addition, in recent years, an emphasis has been placed on modelling the log BB permeation to avoid unethical animal testing. Over the past three decades, various models have been proposed for predicting the BBB permeation and they have suggested different descriptors of the physicochemical properties of substances. Research shows that the penetration of the blood-brain barrier of the compound depends on its hydrogen bonding potential, lipophilicity and size. The BBB penetration is promoted by a weak potential for hydrogen bonding and high lipophilicity [4,5,7–9].

As noted, lipophilicity is one of the most important features affecting the biological activity. Octanol-water partition coefficients (logs $P$) are the most extensively used measure of lipophilicity in modelling the biological partition/distribution. This value can be determined by the classical shake-flask method, which is a time-consuming and tedious procedure. Contrarily, the liquid chromatography is a convenient, reliable and efficient method for assessing the partition parameters that describe the lipophilic properties of organic compounds. The background to this is that the same basic molecular interactions determine the behaviour of the solute in both biological and chromatographic systems. Moreover, there is an increasing evidence of the convenience for modelling pharmacokinetic processes chromatographically, especially by reversed-phase liquid chromatography using biomimetic stationary phases. The octadecysilyl (ODS) stationary phase provides a fast approach, but immobilized artificial membranes (IAMs) are more similar to the membranes of eukaryotic cells and therefore better mimic biological systems [10–12]. Artificial membranes are more similar to biological systems because they anchor synthetic phosphatidylcholine analogues to silica [13–18]. Cholesterol is one of the major components of many eukaryotic membranes and it seems highly likely that cholesterol immobilized on silica would offer similar possibilities. Currently, the stationary phases with immobilized cholesterol are becoming more and more popular and therefore they are increasingly used to study biological properties of different organic compounds [19,20].

All pharmaceutically relevant compounds [19,21–35] were resynthesized in our laboratory for the current research purposes and their structures, belonging to particular groups, are listed in Table 1. They have been shown to possess mainly promising anticancer [19,21–30,32], analgesic [19,21,31,33], antiviral and antihaemolytic [27] activities. Small molecules 1–6 (group I) and 61–65 (group VII) are of particular importance as possible anticancer drug candidates for the treatment of human tumours of lung, cervix, breast and ovary [22–24]. In addition, the most promising structures 1–6 (i.e., showing the minimum embryotoxic concentration higher or comparable to that of aciclovir as well as protective effects on oxidatively-stressed erythrocytes) revealed significant anticancer activities in human tumour cells of pharynx and tongue. The majority of them proved to be more selective than a clinically useful anticancer agent—hydroxycarbamide. Besides, the compound 6 has been shown to possess the remarkable concentration-dependent potency against Herpes simplex virus type 1, while revealing a low toxicity to normal Vero cells and inhibiting the oxidatively-induced haemolysis of erythrocytes [27].
In turn, the confirmed remarkable antiproliferative effects of compounds 12–17 (group III) may be of benefit in the treatment of human multiple myeloma cells that are susceptible and resistant to thalidomide as well as in human tumour cells of cervix and breast [25,26]. Molecules 1, 2, 4, 5, 6, 15, 19, 21, 22, 24, 28, 39, 63 and 64 have been reported as promising anticancer drug candidates, due to not only their proven significant antiproliferative activities in some human cancer cells but also less toxic effects for normal cells [22–27]. Furthermore, test compounds proved to be in vivo active when investigated in the central nervous system. Among analgesic active and relatively low toxic molecules (8–11, 32, 34, 39, 42, 48, 51 and 53), the structures 8, 42 and 51 have been shown to produce the strongest antinociceptive effect in mice [19,21,31,33].

Table 1. Compounds tested.

| Group  | Compound No.; R, R' | Chemical Name                                      | References  |
|--------|---------------------|----------------------------------------------------|-------------|
| Group I| 1: R = H            | 8-(R-phenyl)-3-ethyl-7,8-dihydroimidazo[2,1-          | [22,24,27]  |
|        | 2: R = 4-CH₃        | c][1,2,4]triazin-4(6H)-ones                        |             |
|        | 3: R = 2-Cl         |                                                    |             |
|        | 4: R = 3-Cl         |                                                    |             |
|        | 5: R = 4-Cl         |                                                    |             |
|        | 6: R = 3,4-Cl₂      |                                                    |             |
| Group II| 7: R = H            | Methyl [4-oxo-8-(R-phenyl)                         | [21]        |
|        | 8: R = 4-CH₃        | 4,6,7,8-tetrahydroimidazo[2,1-                      |             |
|        | 9: R = 4-OCH₃       | c][1,2,4]triazin-3-ylacetates                      |             |
|        | 10: R = 4-OCl₂H₃    |                                                    |             |
|        | 11: R = 4-Cl        |                                                    |             |
| Group III| 12: R = H           | Ethyl [4-oxo-8-(R-phenyl)-                          | [25,26]     |
|        | 13: R = 4-CH₃       | 4,6,7,8-tetrahydroimidazo[2,1-                      |             |
|        | 14: R = 4-OCH₃      | c][1,2,4]triazin-3-ylacetates                      |             |
|        | 15: R = 3-Cl        |                                                    |             |
|        | 16: R = 4-Cl        |                                                    |             |
|        | 17: R = 3,4-Cl₂     |                                                    |             |
| Group IV| 18: R = H           | 8-(R-phenyl)-3-(2-furanyl)-7,8-dihydroimidazo[2,1-  | [19,28–30]  |
|        | 19: R = 2-CH₃       | c][1,2,4]triazin-4(6H)-ones                        |             |
|        | 20: R = 4-CH₃       |                                                    |             |
|        | 21: R = 2,3-(CH₃)₂ |                                                    |             |
|        | 22: R = 2-OCH₃      |                                                    |             |
|        | 23: R = 4-OCH₃      |                                                    |             |
|        | 24: R = 2-Cl        |                                                    |             |
|        | 25: R = 3-Cl        |                                                    |             |
|        | 26: R = 4-Cl        |                                                    |             |
|        | 27: R = 3,4-Cl₂     |                                                    |             |
|        | 28: R = 2,6-Cl₂     |                                                    |             |
Table 1. Cont.

| Group    | Compound No.; R, R' | Chemical Name                                                                 | References |
|----------|---------------------|-------------------------------------------------------------------------------|------------|
| Group V  | 29: R = H           | 8-(R-phenyl)-3-phenyl-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-ones     | [19,31–33]|
|          | 30: R = 2-CH₃       |                                                                               |
|          | 31: R = 3-CH₃       |                                                                               |
|          | 32: R = 4-CH₃       |                                                                               |
|          | 33: R = 2-OCH₃      |                                                                               |
|          | 34: R = 4-OCH₃      |                                                                               |
|          | 35: R = 4-OCH₂H₅    |                                                                               |
|          | 36: R = 2,3-(CH₃)₂  |                                                                               |
|          | 37: R = 2-Cl        |                                                                               |
|          | 38: R = 3-Cl        |                                                                               |
|          | 39: R = 4-Cl        |                                                                               |
|          | 40: R = 3,4-Cl₂     |                                                                               |
| Group VI | 41: R = H; R' = H   | 8-(R-phenyl)-3-benzyl/3-(R'-benzyl)-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-ones | [19,21]   |
|          | 42: R = H; R' = 2-Cl|                                                                               |
|          | 43: R = H; R' = 3-Cl|                                                                               |
|          | 44: R = H; R' = 4-Cl|                                                                               |
|          | 45: R = 4-CH₃; R' = H|                                                                               |
|          | 46: R = 4-CH₃; R' = 4-CH₃|                                                     |
|          | 47: R = 4-CH₃; R' = 3-CH₃|                                                      |
|          | 48: R = 4-CH₃; R' = 2-Cl|                                                      |
|          | 49: R = 4-CH₃; R' = 3-Cl|                                                      |
|          | 50: R = 4-CH₃; R' = 4-Cl|                                                      |
|          | 51: R = 4-OCH₂H₅; R' = H|                                                    |
|          | 52: R = 4-OCH₂H₅; R' = 4-CH₃|                                                 |
|          | 53: R = 4-OCH₂H₅; R' = 2-Cl|                                                 |
|          | 54: R = 4-OCH₂H₅; R' = 3-Cl|                                                 |
|          | 55: R = 4-OCH₂H₅; R' = 4-Cl|                                                 |
|          | 56: R = 2-CH₃; R' = 2-Cl|                                                 |
|          | 57: R = 4-Cl; R' = H|                                                 |
|          | 58: R = 4-Cl; R' = 2-Cl|                                                 |
|          | 59: R = 4-Cl; R' = 3-Cl|                                                 |
|          | 60: R = 4-Cl; R' = 4-Cl|                                                 |
| Group VII| 61: R = H           | 8-(R-phenyl)-3-(2-phenylethyl)-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-ones | [22,23]   |
|          | 62: R = 4-CH₃       |                                                                               |
|          | 63: R = 2-Cl        |                                                                               |
|          | 64: R = 4-Cl        |                                                                               |
|          | 65: R = 3,4-Cl₂     |                                                                               |
2. Results

2.1. Chromatographic Results

Retention parameters reported as the log $k$ values were calculated by the expression:

$$\log k = \log \left( \frac{t_R - t_0}{t_0} \right)$$  \hspace{1cm} (1)

where $t_R$ and $t_0$ are the retention times of the solute and a non-retained compound (citric acid), respectively. They were used to calculate the log $k_w$ values, i.e., logarithms of retention parameter in the buffer as the mobile phase. For this purpose the Soczewiński-Wachtmeister’s equation was used [36]:

$$\log k = \log k_w - s\varphi$$  \hspace{1cm} (2)

where $\varphi$ is the volume fraction of organic modifier in the mobile phase; $k$ and $k_w$ are retention parameters corresponding to mixed effluent and buffer as the mobile phase, respectively. The slope $s$ is characteristic of a given solute and chromatographic system. Strong linear relationships between log $k$ and $\varphi$ values were found for all the compounds in the range of effluent composition examined ($R^2 > 0.9$). The log $k_w$ and $s$ values obtained from particular chromatographic systems are presented in Table 2. The log $k_w$ values determined for the ODS ($\log k_w, \text{ODS}$), IAM ($\log k_w, \text{IAM}$) and Cholesterol ($\log k_w, \text{Cholesterol}$) columns were intercorrelated and the following linear relationships with a very good statistical quality were obtained:

$$\log k_w, \text{ODS} = 0.691(\pm 0.094) + 0.982(\pm 0.044) \log k_w, \text{IAM}$$  \hspace{1cm} (3)

$$\text{SD} = 0.257; R^2 = 0.8880; N = 65$$

$$\log k_w, \text{ODS} = 0.911(\pm 0.062) + 0.765(\pm 0.025) \log k_w, \text{Cholesterol}$$  \hspace{1cm} (4)

$$\text{SD} = 0.192; R^2 = 0.9371; N = 65$$

$$\log k_w, \text{IAM} = 0.356(\pm 0.073) + 0.721(\pm 0.029) \log k_w, \text{Cholesterol}$$  \hspace{1cm} (5)

$$\text{SD} = 0.224; R^2 = 0.9068; N = 65$$

### Table 2. Parameters of the Soczewiński-Wachtmeister’s equation obtained for various columns.

| Compound | Tested | ODS | $s_{\text{ODS}}$ | IAM | $s_{\text{IAM}}$ | Cholesterol | $s_{\text{Cholesterol}}$ |
|----------|--------|-----|----------------|-----|----------------|-------------|-------------------------|
| 1        |        | 0.97| 2.70           | 0.55| 2.10           | 0.20        | 1.25                    |
| 2        |        | 1.30| 3.12           | 1.00| 2.88           | 0.57        | 1.84                    |
| 3        |        | 1.22| 3.02           | 0.80| 2.51           | 0.46        | 1.70                    |
| 4        |        | 1.33| 3.15           | 0.84| 2.60           | 0.62        | 1.82                    |
| 5        |        | 1.78| 3.56           | 1.24| 3.25           | 1.18        | 2.61                    |
| 6        |        | 2.53| 4.49           | 1.85| 4.11           | 2.05        | 3.61                    |
| 7        |        | 1.28| 3.09           | 0.81| 2.38           | 0.58        | 1.92                    |
| 8        |        | 1.90| 3.82           | 1.33| 3.33           | 1.29        | 2.75                    |
| 9        |        | 1.30| 3.02           | 0.81| 2.45           | 0.57        | 1.82                    |
| 10       |        | 1.95| 3.91           | 1.42| 3.39           | 1.36        | 2.81                    |
| 11       |        | 2.36| 4.44           | 1.82| 4.39           | 1.82        | 3.55                    |
| 12       |        | 1.75| 3.61           | 1.21| 3.11           | 1.11        | 2.55                    |
| 13       |        | 2.37| 4.36           | 1.70| 3.85           | 1.92        | 3.58                    |
| 14       |        | 1.27| 3.15           | 0.91| 2.58           | 0.65        | 1.92                    |
| 15       |        | 2.85| 4.90           | 2.05| 4.45           | 2.41        | 4.15                    |
| 16       |        | 2.80| 4.88           | 2.11| 4.51           | 2.37        | 4.19                    |
| 17       |        | 3.16| 5.33           | 2.42| 5.01           | 2.77        | 4.61                    |
| 18       |        | 2.12| 4.06           | 1.29| 3.23           | 1.43        | 3.12                    |
Table 2. Cont.

| Compound Tested | ODS | IAM | Cholesterol |
|-----------------|-----|-----|-------------|
|                 | $\log k_{w, ODS}$ | $s_{ODS}$ | $\log k_{w, IAM}$ | $s_{IAM}$ | $\log k_{w, Cholesterol}$ | $s_{Cholesterol}$ |
| 19              | 1.74 | 3.48 | 0.96 | 2.72 | 1.20 | 2.78 |
| 20              | 2.43 | 4.39 | 1.69 | 3.90 | 2.03 | 3.68 |
| 21              | 2.26 | 4.20 | 1.42 | 3.51 | 1.66 | 3.33 |
| 22              | 1.67 | 3.48 | 1.11 | 3.02 | 1.22 | 2.68 |
| 23              | 1.91 | 3.82 | 1.19 | 3.13 | 1.53 | 3.05 |
| 24              | 2.25 | 4.22 | 1.27 | 3.25 | 1.34 | 2.95 |
| 25              | 2.75 | 4.85 | 2.08 | 4.55 | 2.36 | 4.05 |
| 26              | 2.65 | 4.59 | 2.02 | 4.44 | 2.29 | 4.15 |
| 27              | 3.46 | 5.68 | 3.23 | 6.30 | 2.92 | 4.85 |
| 28              | 2.53 | 4.45 | 1.70 | 3.90 | 2.05 | 3.66 |
| 29              | 2.49 | 4.51 | 1.91 | 4.22 | 2.34 | 4.02 |
| 30              | 2.12 | 4.01 | 1.53 | 3.52 | 1.88 | 3.50 |
| 31              | 2.93 | 5.02 | 2.26 | 4.68 | 2.77 | 4.42 |
| 32              | 2.93 | 5.06 | 2.22 | 4.81 | 2.86 | 4.65 |
| 33              | 1.98 | 3.99 | 1.47 | 3.62 | 1.69 | 2.94 |
| 34              | 2.59 | 4.62 | 1.71 | 3.91 | 2.27 | 3.80 |
| 35              | 3.09 | 5.33 | 2.14 | 4.48 | 2.80 | 4.61 |
| 36              | 2.74 | 4.85 | 1.85 | 4.05 | 2.34 | 3.60 |
| 37              | 2.43 | 4.60 | 1.73 | 3.84 | 1.96 | 3.65 |
| 38              | 3.29 | 5.70 | 2.64 | 5.41 | 3.20 | 5.20 |
| 39              | 3.41 | 5.20 | 2.57 | 5.32 | 3.19 | 5.30 |
| 40              | 3.48 | 5.90 | 3.26 | 6.40 | 3.86 | 6.02 |
| 41              | 2.90 | 5.02 | 3.26 | 6.45 | 2.23 | 3.75 |
| 42              | 3.28 | 5.10 | 2.34 | 4.78 | 2.83 | 4.71 |
| 43              | 3.59 | 5.85 | 2.48 | 5.18 | 2.90 | 4.80 |
| 44              | 3.60 | 5.62 | 2.39 | 4.81 | 3.01 | 4.70 |
| 45              | 3.35 | 5.55 | 2.15 | 4.69 | 2.74 | 4.59 |
| 46              | 3.04 | 5.30 | 2.51 | 5.22 | 3.15 | 5.05 |
| 47              | 3.09 | 5.24 | 2.59 | 5.14 | 3.09 | 5.06 |
| 48              | 3.12 | 5.11 | 2.65 | 5.21 | 3.24 | 4.90 |
| 49              | 3.31 | 5.41 | 2.78 | 5.50 | 3.40 | 5.33 |
| 50              | 3.22 | 5.55 | 2.81 | 5.62 | 3.39 | 5.34 |
| 51              | 3.28 | 5.61 | 2.11 | 4.51 | 2.68 | 4.55 |
| 52              | 3.14 | 5.36 | 2.43 | 5.02 | 3.07 | 5.02 |
| 53              | 2.93 | 5.02 | 2.51 | 5.17 | 3.21 | 5.15 |
| 54              | 3.35 | 5.55 | 2.73 | 5.61 | 3.31 | 5.22 |
| 55              | 3.32 | 5.66 | 2.72 | 5.44 | 3.36 | 5.35 |
| 56              | 3.01 | 4.95 | 2.02 | 4.31 | 2.34 | 4.05 |
| 57              | 3.11 | 5.05 | 2.52 | 5.06 | 2.98 | 4.85 |
| 58              | 3.55 | 5.65 | 3.22 | 6.32 | 3.74 | 5.62 |
| 59              | 3.61 | 5.85 | 3.15 | 6.01 | 3.67 | 5.75 |
| 60              | 4.02 | 6.45 | 3.77 | 6.18 | 3.68 | 5.82 |
| 61              | 2.80 | 4.92 | 2.07 | 4.45 | 2.33 | 4.02 |
| 62              | 3.23 | 5.44 | 2.41 | 5.01 | 2.84 | 4.70 |
| 63              | 2.46 | 4.44 | 1.81 | 4.08 | 1.94 | 3.66 |
| 64              | 3.56 | 5.81 | 2.68 | 5.44 | 3.22 | 5.12 |
| 65              | 4.29 | 6.66 | 3.40 | 6.55 | 4.12 | 6.20 |

Moreover highly significant linear relationships were obtained between $\log k_w$ and $s$ values (intercepts and slopes of Equation (2)):

for the ODS column:

$$\log k_{w, ODS} = -1.214(\pm 0.062) + 0.823(\pm 0.013) s_{ODS}$$

$$SD = 0.094; R^2 = 0.9850; N = 65$$

for the IAM column:

$$\log k_{w, IAM} = -0.779(\pm 0.026) + 0.638(\pm 0.006) s_{IAM}$$
and for the Cholester column:

\[
\log k_{w, \text{Cholester}} = -0.892(\pm 0.040) + 0.798(\pm 0.010) \times \text{Cholester}
\]  

(8)

\[
\text{SD} = 0.092; \ R^2 = 0.9910; \ N = 65
\]

2.2. Establishment of the LFER Model

The property of the substance can be predicted on the basis of the linear free-energy relationships (LFER), but to do so, the relationship between the chemical structure and the desired property should be identified [37]. A symbolic representation of LFERs model is the equation originally employed by Abraham et al. [38–42]:

\[
\text{SP} = c + eE + sS + aA + bB + vV
\]  

(9)

Here SP is a set of solute properties in a given system, e.g., \( \log BB \) values. The independent values are solute descriptors: \( E \) is an excess molar refraction, \( S \) is the dipolarity/polarizability, \( A \) and \( B \) are the hydrogen bond acidity (donating ability) and basicity (accepting ability), respectively and \( V \) is the solute McGowan volume (\( \text{cm}^3\cdot\text{mol}^{-1}/100 \)). Coefficients \( c, e, s, a, b \) and \( v \) are characteristic for a given biphasic system and solute.

In this study, this equation was established for a training set of 23 azole compounds that were congeneric with those tested in our investigations. For these compounds, we obtained from the literature [43] the experimental \( \log BB \) (\( BB = C_{\text{brain}}/C_{\text{plasma}} \)) values for rats (Table 3). The actual values of \( \log BB \) ranged from \( -0.82 \) to \( 0.58 \). The following MLR equation was obtained:

\[
\log BB_{\exp} = 0.934(\pm 0.166) + 0.191(\pm 0.107)E - 0.605(\pm 0.134)S - 0.743(\pm 0.137)A - 0.768(\pm 0.177)B + 0.545(\pm 0.104)V
\]  

(10)

\[
N = 23; \ \text{SD} = 0.134; \ R^2 = 0.9039; \ F = 32; \ p < 10^{-5}
\]

| No. | CAS #       | A      | B      | S      | E      | V      | \( \log BB_{\exp} \) |
|-----|-------------|--------|--------|--------|--------|--------|-----------------------|
| 1   | 23830-88-8  | 0.45   | 0.90   | 1.22   | 1.56   | 1.5317 | 0.16                  |
| 2   | 21571-08-4  | 0.45   | 0.86   | 1.30   | 1.690  | 1.6541 | 0.47                  |
| 3   | 38941-33-2  | 0.45   | 0.86   | 1.54   | 2.240  | 1.8119 | 0.58                  |
| 4   | 4205-93-0   | 0.39   | 0.90   | 1.36   | 1.920  | 1.6369 | 0.33                  |
| 5   | 40065-09-6  | 0.45   | 0.86   | 1.38   | 1.870  | 1.7067 | 0.41                  |
| 6   | 4205-90-7   | 0.55   | 1.16   | 1.34   | 1.600  | 1.5317 | 0.19                  |
| 7   | 73950-58-6  | 0.35   | 2.05   | 3.18   | 2.670  | 2.5161 | 0.82                  |
| 8   | 28981-97-7  | 0      | 1.55   | 2.50   | 2.896  | 2.2041 | -0.04                 |
| 9   | 84379-13-5  | 0      | 1.55   | 2.84   | 2.520  | 2.7008 | -0.09                 |
| 10  | 78755-81-4  | 0      | 1.50   | 2.63   | 1.910  | 2.0884 | -0.29                 |
| 11  | 59467-70-8  | 0      | 1.38   | 2.01   | 2.570  | 2.2628 | 0.32                  |
| 12  | 99632-94-7  | 0      | 1.48   | 2.52   | 1.920  | 2.2773 | -0.25                 |
| 13  | 2507-81-5   | 0.65   | 0.94   | 1.52   | 1.906  | 1.6051 | -0.15                 |
| 14  | 112598-30-8 | 0.40   | 1.69   | 2.16   | 2.070  | 2.0043 | -0.66                 |
| 15  | 7120-01-6   | 0.75   | 0.80   | 1.00   | 1.205  | 1.1382 | -0.04                 |
| 16  | 108076-38-2 | 0.40   | 1.38   | 2.64   | 2.689  | 2.9946 | 0.14                  |
| 17  | 108076-32-6 | 0.40   | 1.40   | 2.69   | 2.694  | 2.8998 | 0.22                  |
| 18  | 133099-04-4 | 0.49   | 1.58   | 2.82   | 2.800  | 2.9797 | -0.62                 |
| 19  | 142494-12-0 | 0.00   | 1.73   | 1.83   | 1.490  | 2.6577 | 0.16                  |
| 20  | 486-56-6    | 0.00   | 1.38   | 1.49   | 1.049  | 1.3867 | 0.04                  |
| 21  | 54-11-5     | 0.00   | 1.08   | 0.92   | 0.865  | 1.3710 | 0.56                  |
| 22  | 494-97-3    | 0.13   | 0.85   | 1.02   | 0.990  | 1.2301 | 0.32                  |
| 23  | 58-08-2     | 0.05   | 1.28   | 1.72   | 1.500  | 1.3632 | 0.01                  |
Irrelevant cross correlations between the descriptors were observed; the values of $R^2$ between pairs of descriptors were $E/S$ 0.66, $E/A$ 0.01, $E/B$ 0.25, $E/V$ 0.60, $S/A$ 0.06, $S/B$ 0.69, $S/V$ 0.72, $A/B$ 0.20, $A/V$ 0.05 and $B/V$ 0.49. This is an important information indicating that there are no significant inter-correlations of structural descriptors, i.e., $E$, $S$, $A$, $B$ and $V$. On this basis, we can conclude that non-physical factors do not affect the parameters of Equation (10). The reliability and predictive potency of the model expressed by Equation (10) were estimated by leave-one-out (LOO) cross validation and the parameters that were obtained are presented in Table 4. Figure 1 shows the standardized coefficients for particular descriptors and it confirms the well-known qualitative relationships: compound polarity, i.e., dipolarity/polarizability, hydrogen bond acidity and hydrogen bond basicity expressed by $S$, $A$ and $B$ values, respectively, decreases the BBB permeation, while the compound size measured by the McGovan volume ($V$) as well as the excess molar refraction $E$ (in a minor degree) contribute to increase of log $BB$ values [41]. The PLS response plot is presented in Figure 2, which shows the linear regression between the predicted (calculated response) and experimental log $BB$ values of the 23 compounds from Table 3. The residual versus leverage plot in Figure 3 proves that the model that was obtained is valid for the domain in which it was developed [44]. The warning leverage limit ($h^*$) was calculated according to:

$$h^* = \frac{3m}{n}$$

where $m$ is the number of descriptors and $n$ is the number of observations (compounds) in the dataset.

| MLR Model | Statistical Parameters | Values |
|-----------|------------------------|--------|
| Equation (10) | $N$ | 23 |
| | $R^2$ | 0.9039 |
| | $Q^2$ | 0.8756 |
| | MSE | 0.01784 |
| | PRESS* | 0.55198 |
| | MSEcv* | 0.01784 |
| | $N$ | 65 |
| | $R^2$ | 0.8474 |
| | $Q^2$ | 0.8398 |
| Equation (12) | MSE | 0.00481 |
| | PRESS* | 0.3272 |
| | PRESS** | 0.3076 |
| | MSEcv* | 0.004799 |
| | MSEcv** | 0.004799 |
| | $N$ | 65 |
| | $R^2$ | 0.8469 |
| | $Q^2$ | 0.8394 |
| Equation (13) | MSE | 0.00482 |
| | PRESS* | 0.3293 |
| | PRESS** | 0.3100 |
| | MSEcv* | 0.004841 |
| | MSEcv** | 0.004841 |
| | $N$ | 65 |
| | $R^2$ | 0.8471 |
| | $Q^2$ | 0.8396 |
| Equation (14) | MSE | 0.00482 |
| | PRESS* | 0.3270 |
| | PRESS** | 0.3067 |
| | MSEcv* | 0.004817 |
| | MSEcv** | 0.004817 |

Table 4. Statistical parameters of cross-validation of MLR models described by Equations (10), (12), (13) and (14); MSE—mean square error, MSEcv*—mean square error of leave-one-out cross validation, MSEcv**—mean square error of leave-50%-out cross validation, PRESS*—predicted residual sum of squares of leave-one-out cross validation, PRESS**—predicted residual sum of squares of leave-50%-out cross validation.
Figure 1. PLS standardized coefficient plot (Equation (10)).

Figure 2. PLS response plot (Equation (10)).

Equation (10) was used to calculate the log $BB$ values for our 65 pharmaceutically relevant compounds (Table 5).

Table 5. Values of $A$, $B$, $S$, $E$, $V$, topological polar surface area (TPSA), polarizability ($\alpha$), molecular weight (MW) and log $BB$ of tested compounds.

| Comp. Tested | $A$ | $B$ | $S$ | $E$ | $V$ | TPSA [Å$^2$] | $\alpha$ [Å$^3$] | MW [g/mol] | log $BB$ calculated |
|--------------|-----|-----|-----|-----|-----|--------------|--------------|------------|-------------------|
|              |     |     |     |     |     |              |              |           | Equation (10)     |
|              |     |     |     |     |     |              |              |           | Equation (12)     |
|              |     |     |     |     |     |              |              |           | Equation (13)     |
|              |     |     |     |     |     |              |              |           | Equation (14)     |
| 1            | 0   | 1.34| 1.73| 1.88| 1.8144| 48.27        | 27.55        | 242.28    | 0.21 0.19 0.20 0.22 |
| 2            | 0   | 1.34| 1.67| 1.90| 1.9553| 48.27        | 29.30        | 256.30    | 0.32 0.21 0.22 0.24 |
| 3            | 0   | 1.33| 1.81| 2.01| 1.9368| 48.27        | 29.37        | 276.72    | 0.26 0.21 0.22 0.24 |
| 4            | 0   | 1.28| 1.80| 2.01| 1.9368| 48.27        | 29.37        | 276.72    | 0.30 0.21 0.22 0.24 |
| 5            | 0   | 1.33| 1.84| 2.03| 1.9368| 48.27        | 29.37        | 276.72    | 0.24 0.21 0.22 0.24 |
| 6            | 0   | 1.26| 1.91| 2.14| 2.0929| 48.27        | 31.20        | 311.17    | 0.34 0.24 0.24 0.26 |
| 7            | 0   | 1.67| 2.13| 1.94| 2.0297| 74.57        | 30.27        | 286.29    | -0.16 -0.13 -0.11 -0.10 |
| 8            | 0   | 1.67| 2.07| 1.97| 2.1706| 74.57        | 32.02        | 300.31    | -0.04 -0.11 -0.09 -0.08 |
| 9            | 0   | 1.88| 2.26| 2.01| 2.2293| 83.80        | 32.57        | 316.31    | -0.28 -0.23 -0.21 -0.20 |
| 10           | 0   | 1.88| 2.26| 2.01| 2.3702| 83.80        | 34.40        | 330.34    | -0.20 -0.21 -0.19 -0.17 |
| 11           | 0   | 1.65| 2.24| 2.09| 2.1521| 74.57        | 32.09        | 320.73    | -0.12 -0.10 -0.09 -0.07 |
| 12           | 0   | 1.68| 2.14| 1.94| 2.1706| 74.57        | 32.09        | 300.31    | -0.10 -0.11 -0.09 -0.07 |
| 13           | 0   | 1.68| 2.08| 1.96| 2.3115| 74.57        | 33.85        | 314.38    | 0.02 -0.09 -0.07 -0.05 |
| 14           | 0   | 1.88| 2.24| 1.98| 2.3702| 83.80        | 34.40        | 330.34    | -0.20 -0.21 -0.20 -0.18 |
| 15           | 0   | 1.62| 2.20| 2.07| 2.2930| 74.57        | 33.92        | 334.76    | 0.00 -0.08 -0.07 -0.05 |
| 16           | 0   | 1.66| 2.25| 2.09| 2.2930| 74.57        | 33.92        | 334.76    | -0.05 -0.08 -0.07 -0.05 |
| 17           | 0   | 1.59| 2.32| 2.20| 2.4154| 74.57        | 35.74        | 369.20    | 0.05 -0.06 -0.05 -0.03 |
| 18           | 0   | 1.46| 2.07| 2.24| 1.9603| 61.41        | 30.82        | 280.31    | 0.06 0.06 0.07 0.09 |
| 19           | 0   | 1.46| 2.01| 2.26| 2.1012| 61.41        | 32.57        | 294.34    | 0.17 0.07 0.08 0.10 |
| 20           | 0   | 1.46| 2.01| 2.26| 2.1012| 61.41        | 32.57        | 294.34    | 0.17 0.08 0.08 0.11 |
| 21           | 0   | 1.46| 1.95| 2.29| 2.2421| 61.41        | 34.33        | 308.37    | 0.29 0.09 0.10 0.12 |
| 22           | 0   | 1.66| 2.17| 2.28| 2.1599| 70.64        | 33.12        | 310.34    | -0.04 -0.05 -0.03 -0.02 |
| 23           | 0   | 1.66| 2.19| 2.31| 2.1599| 70.64        | 33.12        | 310.34    | -0.05 -0.05 -0.03 -0.01 |
| 24           | 0   | 1.45| 2.15| 2.36| 2.0827| 61.41        | 32.64        | 314.75    | 0.11 0.07 0.08 0.10 |
| 25           | 0   | 1.40| 2.13| 2.36| 2.0827| 61.41        | 32.64        | 314.75    | 0.16 0.08 0.09 0.11 |
| 26           | 0   | 1.45| 2.18| 2.39| 2.0827| 61.41        | 32.64        | 314.75    | 0.09 0.08 0.09 0.11 |
| 27           | 0   | 1.38| 2.25| 2.50| 2.2051| 61.41        | 34.47        | 349.20    | 0.19 0.10 0.11 0.13 |
| 28           | 0   | 1.38| 2.22| 2.48| 2.2051| 61.41        | 34.47        | 349.20    | 0.21 0.09 0.10 0.12 |
| 29           | 0   | 1.42| 2.19| 2.46| 2.1804| 48.27        | 33.92        | 290.32    | 0.15 0.26 0.27 0.29 |
| 30           | 0   | 1.43| 2.13| 2.48| 2.2813| 48.27        | 35.68        | 304.35    | 0.26 0.27 0.28 0.30 |

Figure 3. PLS residual vs. leverage (Equation (10)).
2.3. Establishment of QSARs Models

Efforts to predict the biological activity (including the BBB permeation) based on the properties of substances led to the development of Quantitative Structure Activity Relationships (QSARs) and Quantitative Retention Activity Relationships (QRARs) methodology [37,44–48]. Various models and approaches have been developed to predict the penetration of the blood-brain barrier based on various physicochemical properties of molecules, including the lipophilicity, molecular size, polarizability, polar surface area and the number of groups that can establish potential hydrogen bonds [49–63]. It is reasonable to assume that the combination of theoretical and experimental data increases the reliability of the anticipated transport of the drug across the blood-brain barrier [64–66]. The chromatographic retention parameter is one of the most popular experimental values used to characterize the properties (lipophilicity/hydrophobicity) of compounds used in QRAR and QSAR studies. The solute retention depends on the changes in free energy that are associated with the distribution of the solute between the mobile and stationary phases in a given chromatographic system. Thus, it is possible to use the values obtained on HPLC columns that imitate biomembranes for modelling the blood-brain barrier permeation.

In our investigations in which we modelled the blood-brain permeation of 65 biologically active molecules, the chromatographic lipophilicity ($\log k_w$) (Table 2), polarizability ($\alpha$) and topological polar surface area (TPSA) (Table 5) were considered. The following MLR equations corresponding to various stationary phases were obtained:

for ODS column:

$$
\log BB = 0.587(\pm 0.127) + 0.011(\pm 0.020) \log k_w - 0.013(\pm 0.001) \text{TPSA} + 0.008(\pm 0.004) \alpha
$$

\[\text{(Equation 12)}\]
\[ N = 65; \text{SD} = 0.069; R^2 = 0.8474; F = 113; p < 10^{-6}; \text{VIF} < 3.1 \]

for IAM column:

\[
\log BB = 0.578(\pm 0.127) + 0.007(\pm 0.019) \log k_{w, \text{IAM}} - 0.013(\pm 0.001) \text{TPSA} + 0.009(\pm 0.004) \alpha \tag{13}
\]

\[ N = 65; \text{SD} = 0.069; R^2 = 0.8469; F = 113; p < 10^{-6}; \text{VIF} < 2.7 \]

and for Cholesterol column:

\[
\log BB = 0.595(\pm 0.139) + 0.008(\pm 0.017) \log k_{w, \text{Cholesterol}} - 0.013(\pm 0.001) \text{TPSA} + 0.009(\pm 0.004) \alpha \tag{14}
\]

\[ N = 65; \text{SD} = 0.069; R^2 = 0.8471; F = 113; p < 10^{-6}; \text{VIF} < 3.7 \]

The statistics of Equations (12)–(14) were very good, i.e., \( R^2 > 0.8 \) for all chromatographic systems and all variance inflation factors (VIF < 5) indicated that the variables were correlated moderately. The reliability of the MLR models, as expressed by Equations (12)–(14), were estimated by leave-one-out as well as leave-50%-out cross validation (Table 4). In each case, the \( \log k_w \) and \( \alpha \) values provided positive inputs to the \( \log BB \), while TPSA decreased the permeation of the blood-brain barrier (Figure 4).
Figure 4. PLS standardized coefficient plots obtained for Equation (12) (A), Equation (13) (B) and Equation (14) (C).

The relationships showed that molecular polarizability and lipophilicity promote increases in the log \( BB \), while polar surface area decreased the ability of a substance to cross the BBB. The correlations between the log \( BB \) values calculated according to the LFER model (Equation (10)) and the optimized QSARs models, i.e., by Equations (12)–(14) are presented in Figures 5–7, which shows the response plots obtained by PLS for particular stationary phases.
Figure 5. Cont. PLS response plots obtained for Equation (12).

Figure 6. Cont.
Figure 6. PLS response plots obtained for Equation (13).

Figure 7. Cont.
To assess the significance of chromatographic parameters, the lipophilicity descriptors, log $k_w$ were compared with partition coefficients in the n-octanol-water system, i.e., the log $P$ values. The relationships between log $P$ values calculated from molecular structures of the tested compounds and obtained by use of Alog $P_s$ algorithm [67,68] and their chromatographic factors (i.e., log $k_w$, ODS, log $k_w$, IAM and log $k_w$, Cholesterol, respectively) were established. Good linear correlations between these descriptors ($R > 0.8$), that are observed in Figure 8, confirmed that chromatographic parameters can be used as lipophilicity descriptors in case of the studied compounds (Figure 8).

Moreover the following QSAR equation including Alog $P_s$, TPSA and $\alpha$ descriptors was established:

$$\log BB = 0.627(\pm 0.115) + 0.077(\pm 0.028) \text{Alog } P_s - 0.012(\pm 0.001) \text{TPSA} + 0.001(\pm 0.004) \alpha \quad (15)$$

$N = 65$; $SD = 0.065$; $R^2 = 0.8639$; $F = 130$; $p < 10^{-6}$; $VIF < 4.3$; $Q^2 = 0.8572$; MSE = 0.004287; $\text{MSEcv}^* = 0.004218$; $\text{MSEcv}^{**} = 0.004218$; $\text{PRESS}^* = 0.2900$; $\text{PRESS}^{**} = 0.2698$.

The statistics of Equation (15) proved to be very good and similar to those obtained for Equations (12)–(14), which confirms their ability in predicting the blood brain barrier permeation.
Figure 7. Cont. PLS response plots obtained for Equation (14). The relationships showed that molecular polarizability and lipophilicity promote increases in the log BB, while polar surface area decreased the ability of a substance to cross the BBB. The correlations between the log BB values calculated according to the LFER model (Equation (10)) and the optimized QSARs models, i.e., by Equations (12)–(14) are presented in Figures 5–7, which shows the response plots obtained by PLS for particular stationary phases.

Figure 8. Alog Ps vs. log kw relationships obtained for ODS, IAM and Cholester columns.

3. Materials and Methods

3.1. Reagents

Acetonitrile (HPLC grade) was purchased from Merck (Lublin, Poland). Citric acid and Na₂HPO₄ (both pure) were supplied from POCh (Lublin, Poland). Distilled water was obtained from Direct-Q3 UV apparatus (Millipore, Warsaw, Poland).

3.2. Instrumental

Shimadzu Vp (Shimadzu, Izabelin, Poland) liquid chromatographic system equipped with LC 10AT pump, SPD 10A UV-Vis detector, SCL 10A system controller, CTO-10 AS chromatographic oven and Rheodyne injector valve with a 20 µL loop was applied in HPLC measurements. Three stationary phases were employed:
- Purosphere RP-18e (ODS), 125 × 4 mm i.d., 5 µm (Merck);
- IAM.PC.DD2 100 × 4.6 mm i.d., 10 µm (Regis Chemicals Company, Morton Grove, IL, USA);
- Cosmosil Cholester, 75 × 2 mm i.d., 2.5 µm (Genore, Warsaw, Poland).

3.3. Chromatographic Conditions and Test Substances

As mobile phases buffer-acetonitrile mixtures were used. The buffer was prepared from 0.01 mol L⁻¹ solutions of Na₂HPO₄ and citric acid and the pH 7.4 value was fixed before mixing with organic modifier. With the ODS column acetonitrile concentration in the effluent, expressed as a volume fraction (ϕ, v/v), was changed in the range 0.3–0.6, with the constant step of 0.1. The flow rate was 1 mL min⁻¹. With the IAM column acetonitrile concentration was changed in the range 0.2–0.5, also with the constant step of 0.1 and the flow rate was 1.3 mL min⁻¹. With the Cosmosil Cholester column acetonitrile concentration was changed in the range 0.4–0.6, with the constant step of 0.05 and the flow rate was 0.4 mL min⁻¹. Samples of test compounds were dissolved in acetonitrile—c.a. 0.005 mg mL⁻¹. All the compounds proved to be in the neutral form in solution under experimental
conditions and had values of peak asymmetry factor in the acceptable range. They were detected under UV light at 210 and 254 nm. All measurements were carried out at 25 °C. The dead time values were measured from non-retained compound (citric acid) peaks. All reported log \( k_w \) values are the average of at least three independent measurements. The extrapolated retention coefficients (logs \( k_w \)) achieved by HPLC on ODS, IAM and Cholesterol stationary phases were used for modelling the log \( BB \) permeation of 65 drug-like compounds employed as a whole test set (Table 1).

3.4. In silico Calculations

Molecular descriptors (\( E, S, A, B \) and \( V \)), molecular weight (MW), topological polar surface area (TPSA) and polarizability (\( \alpha \)) of compounds were evaluated by ACD/Percepta software (Łódź, Poland).

3.5. Statistical Analysis

Linear regression, multiple linear regression (MLR), partial last square (PLS), leave-one-out (LOO) and leave-50%-out cross validation were performed using Minitab 16 software (Minitab Inc., State College, PA, USA).

4. Discussion

The usefulness of HPLC with three different reverse-phase columns (including two imitating biosystems) for predicting the blood-brain barrier (BBB) permeability of 65 structurally related drug-like molecules was highlighted in our investigations. QSAR models predicting the BBB permeation were built on the basis of experimentally accessible log \( k_w \) values of the test molecules together with their important in silico molecular descriptors. The obtained results confirmed that all three stationary phases, i.e., octadecylsilane, immobilized artificial membrane and cholesterol immobilized on silica gel analogously described the lipophilic properties of the studied solutes (Equations (3)–(5)).

In our studies the extrapolated retention parameters (logs \( k_w \)) were used as they are preferred in QSARs instead of the isocratic log \( k \) values and usually employed in correlation studies with in silico molecular descriptors and drug-likeness properties in case of pharmaceutics and drug-like molecules. It should be noted that chromatographically derived retention parameters are very useful descriptors in QSAR modelling as the partitioning process between the stationary and mobile phase of a solute investigated mimics a membrane penetration process of a pharmaceutic or potential drug candidate [19,21,33,37].

Highly significant linear relationships were obtained between intercepts and slopes of Equation (2), i.e., the log \( k_w \) and \( s \) values, for particular reversed-phase stationary phases. These correlations confirmed not only the congenereity between compounds that were investigated, but also suggested that the log \( k_w \) and \( s \) values may be considered as alternative lipophilicity descriptors [19,21,37] in case of structurally related small molecules that were tested. In our studies compounds bearing more hydrophobic substituents revealed the greater \( s \) values. This observation is consistent with other research findings showing that more hydrophobic molecules reveal greater slopes [21]. According to the background retention theory the \( s \) values are related to the solute/mobile phase and the solvent/stationary phase net interactions [21,36,37].

The obtained results showed that the chromatographic retention parameters obtained using three stationary phases recruited as well as important in silico molecular descriptors can be recommended to derive the reliable QSAR models for predicting the blood-brain barrier permeability in case of our structurally related small molecules, considered as a test set of potential drug candidates.

The calculated log \( P \) values were obtained by using Alog \( P_x \) algorithm and compared with the experimental log \( k_{w, ODS} \), log \( k_{w, IAM} \) and log \( k_{w, Cholesterol} \) values, respectively. This estimation was essential to check the validity of the obtained results through correlation with the log \( BB \) values.
5. Conclusions

Experimental literature data of the log BB (for rats) for a training set of 23 biologically active compounds (including drugs) were correlated against five solute descriptors (E, S, A, B and V) and the established equation (Equation (10)) was validated. The standardized coefficients obtained for particular descriptors confirmed that the compound polarity, i.e., dipolarity/polarizability (S), hydrogen bond acidity (A) and hydrogen bond basicity (B) decreases the blood-brain barrier (BBB) permeation while the compound size measured by the McGovan volume (V) and the excess molar refraction (E) contribute to increase in the log BB values. The Equation (10) was used to calculate the log BB values for 65 newly synthesized compounds being considered as potential drugs.

The blood-brain barrier permeability of the compounds that were tested was modelled by three descriptors, i.e., the chromatographic lipophilicity (log \( k_w \)), polarizability (\( \alpha \)) and topological polar surface area (TPSA). Using a simple statistical model (i.e., MLR), three structure-activity relationships were obtained for each chromatographic system on endcapped octadecylsilyl, immobilized artificial membrane and cholesteryl stationary phases (Equations (12)–(14)). The log BB values calculated according to Equation (10) and predicted from Equations (12)–(14) were compared and highly significant relationships were obtained between them. The relationships were confirmed by leave-one-out as well as leave-50%-out cross validation, implying that the models are robust and reliable. The results that were obtained showed that, in the case of the compounds that were studied (65 weak organic bases), each of the stationary phases used in the chromatographic measurements was equally useful. From practical and economic perspectives, the Cholesterol microcolumn is recommended because it allows the acquisition of more data in a shorter time with lower costs.

We showed that it is possible to use the HPLC technique to build a reliable model for predicting which our organic compounds (congeneric in structure to the training set of azole molecules) can penetrate the blood-brain barrier in rats. The investigations highlighted the key role of chromatographic techniques and QSARs methods in reducing unethical animal testing.

The presented results will be particularly useful in further more extensive in vivo research, which is planned to be carried out on our small molecules considered as potential drugs.

Author Contributions: Conceptualization, M.J.; Methodology, M.J.; Investigation, M.J.; Formal analysis, M.J.; Funding acquisition, M.S., K.S.; Resources, M.J., M.S., K.S.; Writing—Original Draft, M.J., M.S., K.S.; Writing—Review & Editing, M.J., M.S., K.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Sugano, K.; Kansy, M.; Artursson, P.; Avdeef, A.; Bendels, S.; Di, L.; Ecker, G.F.; Faller, B.; Fischer, H.; Geretzboff, G.; et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discov. 2010, 9, 597–614. [CrossRef]
2. Sugiyama, Y.; Kusuhara, H.; Suzuki, H. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: Importance in the drug delivery to the brain. J. Contr. Rel. 1999, 62, 179–186. [CrossRef]
3. Seddon, A.M.; Casey, D.; Law, R.V.; Gee, A.; Templer, R.H.; Cesab, O. Drug interactions with lipid membranes. Chem. Soc. Rev. 2009, 38, 2509–2519. [CrossRef] [PubMed]
4. Wolak, D.J.; Thorne, R.G. Diffusion of macromolecules in the brain: Implications for drug delivery. Mol. Pharm. 2013, 10, 1492–1504. [CrossRef] [PubMed]
5. Banks, W.A. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009, 9 (Suppl. 1), S3. [CrossRef] [PubMed]
6. Konovalov, D.A.; Coomans, D.; Deconinck, E.; Heyden, Y.V. Benchmarking of QSAR Models for Blood-Brain Barrier Permeation. J. Chem. Inf. Model. 2007, 47, 1648–1656. [CrossRef] [PubMed]
7. Goodwin, J.T.; Clark, D.E. In Silico Predictions of Blood-Brain Barrier Penetration: Considerations to “Keep in Mind”. *J. Pharm. Exp. Therap.* 2005, 315, 477–483. [CrossRef] [PubMed]
8. Abbott, N.J. ADME-Tox Approaches. In *Comprehensive Medicinal Chemistry II*, 2nd ed.; Taylor, J.B., Triggle, D.J., Eds.; Elsevier LTD: Amsterdam, The Netherlands, 2007; pp. 301–320.
9. Bickel, U. How to Measure Drug Transport across the Blood-Brain Barrier. *NeuroRx* 2005, 2, 15–26. [CrossRef]
10. Liu, X.; Testa, B.; Fahr, A. Lipophilicity and its relationship with passive drug permeation. *Pharm. Res.* 2011, 28, 962–977. [CrossRef]
11. Grumetto, L.; Russo, G.; Barbato, F. Immobilized Artificial Membrane HPLC Derived Parameters vs PAMPA-BBB Data in Estimating in Situ Measured Blood-Brain Barrier Permeation of Drugs. *Mol. Pharm.* 2016, 13, 2808–2816. [CrossRef]
12. Russo, G.; Grumetto, L.; Szucs, R.; Barbato, F.; Lynen, F. Screening therapeutics according to their uptake across the blood-brain barrier: A high throughput method based on immobilized artificial membrane liquid chromatography-diode-array-detection coupled to electrospray-time-of-flight mass spectrometry. *Eur. J. Pharm. Biopharm.* 2018, 127, 72–84. [CrossRef] [PubMed]
13. Ong, S.; Liu, H.; Pidgeon, C. Immobilized-artificial-membrane chromatography: Measurements of membrane partition coefficient and predicting drug membrane permeability. *J. Chromatogr. A* 1996, 728, 113–128. [CrossRef]
14. Yang, C.Y.; Cai, S.J.; Liu, H.; Pidgeon, C. Immobilized Artificial Membranes – screens for drug membrane interactions. *Adv. Drug Del. Rev.* 1996, 23, 229–256. [CrossRef]
15. Taillardat-Bertschinger, A.; Galland, A.; Carrupt, P.-A.; Testa, B. Immobilized artificial membrane liquid chromatography: Proposed guidelines for technical optimization of retention measurements. *J. Chromatogr. A* 2002, 953, 39–53. [CrossRef]
16. Verzele, D.; Lynen, F.; De Vrieze, M.; Wright, A.G.; Hanna-Brown, M.; Sandra, P. Development of the first sphingomyelin biomimetic stationary phase for immobilized artificial membrane (IAM) chromatography. *Chem. Commun.* 2012, 48, 1162–1164. [CrossRef]
17. De Vrieze, M.; Lynen, F.; Chen, K.; Szucs, R.; Sandra, P. Predicting drug penetration across the blood-brain barrier: Comparison of micellar liquid chromatography and immobilized artificial membrane liquid chromatography. *Anal. Bioanal. Chem.* 2013, 405, 6029–6041. [CrossRef]
18. De Vrieze, M.; Verzele, D.; Szucs, R.; Sandra, P.; Lynen, F. Evaluation of sphingomyelin, cholesterol and phosphatidylcholine-based immobilized artificial membrane liquid chromatography to predict drug penetration across the blood-brain barrier. *Anal. Bioanal. Chem.* 2014, 406, 6179–6188. [CrossRef]
19. Janicka, M.; Sztanke, M.; Sztanke, K. Reversed-phase liquid chromatography with octadecylsilyl, immobilized artificial membrane and cholesterol columns in correlation studies with in silico biological descriptors of newly synthesized antiproliferative and analgesic active compounds. *J. Chromatogr. A* 2013, 1318, 92–101. [CrossRef]
20. Janicka, M.; Pachuta-Stec, A. Retention-property relationships of 1,2,4-triazoles by micellar and reversed-phase liquid chromatography. *J. Sep. Sci.* 2014, 37, 1419–1428. [CrossRef]
21. Sztanke, M.; Tuzimski, T.; Janicka, M.; Sztanke, K. Structure-retention behaviour of biologically active fused 1,2,4-triazinones – Comparison with in silico molecular properties. *Eur. J. Pharm. Sci.* 2015, 68, 114–126. [CrossRef]
22. Sztanke, M.; Rzymowska, J.; Janicka, M.; Sztanke, K. Synthesis, structure confirmation, identification of in vitro antiproliferative activities and correlation of determined lipophilicity parameters with in silico bioactivity descriptors of two novel classes of fused azaisocytosine-like congeners. *Arab. J. Chem.* 2016. [CrossRef]
23. Sztanke, M.; Sztanke, K.; Medical University of Lublin. 3-(2-Phenylethyl)-8-aryl-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-ones, Method for Obtaining them and Medical Application. Polish Patent 224678, 31 January 2017.
24. Sztanke, M.; Sztanke, K.; Medical University of Lublin. 3-Ethyl-8-aryl-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-ones, Method for Obtaining them and Medical Application. Polish Patent 224679, 31 January 2017.
25. Sztanke, K.; Sztanke, M.; Medical University of Lublin. Ethyl 2-(4-oxo-4,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3-yl)acetates, Method for Obtaining them and Medical Application. Polish Patent 219424, 30 April 2015.
26. Sztanke, M.; Rzymowska, J.; Sztanke, K. Synthesis, structure elucidation and in vitro anticancer activities of novel derivatives of diethyl (2E)-2-[(2E)-(1-arylimidazolidin-2-ylidene)hydrazono]succinate and ethyl (4-oxo-8-aryl-4,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3-yl)acetate. *Bioorg. Med. Chem.* 2013, 21, 7465–7480. [CrossRef] [PubMed]

27. Sztanke, M.; Sztanke, K.; Rajtar, B.; Świątek, Ł.; Boguszewska, A.; Polz-Dacewicz, M. The influence of some promising fused azaisocytosine-containing congeners on zebrafish (*Danio rerio*) embryos/larvae and their antihaemolytic, antitumour and antiviral activities. *Eur. J. Pharm. Sci.* 2019, 132, 34–43. [CrossRef] [PubMed]

28. Sztanke, K.; Tuzimski, T.; Sztanke, M.; Rzymowska, J.; Pasternak, K. Synthesis, structure elucidation, determination of the lipophilicity and identification of antitumour activities in vitro of novel 3-(2-furanyl)-8-aryl-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-ones with a low cytotoxicity towards normal human skin fibroblast cells. *Bioorg. Med. Chem.* 2011, 19, 5103–5116.

29. Sztanke, K.; Sztanke, M.; Pasternak, K.; Medical University of Lublin. 3-(2-Furanyl)-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-ones Substituted with Mono- or Dichlorophenyl and Process for the Preparation Thereof. Polish Patent PL 212442, 31 October 2012.

30. Sztanke, K.; Sztanke, M.; Pasternak, K.; Medical University of Lublin. Derivatives of 3-(2-furanyl)-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one Substituted with phenyl, Alkylphenyl, Alkoxyphenyl and Process for the Preparation Thereof. Polish Patent PL 212447, 31 October 2012.

31. Sztanke, K.; Medical University of Lublin. New 8-aryl-3-phenyl-6,7-dihydro-4H-imidazo[2,1-c][1,2,4]triazine-4-ones and Methods for their Manufacture. Polish Patent PL 199750, 31 October 2008.

32. Sztanke, K.; Pasternak, K.; Sztanke, M.; Kandefer-Szerszeń, M.; Koziol, A.E.; Dybala, I. Crystal structure, antitumour and antimetastatic activities of disubstituted fused 1,2,4-triazinones. *Bioorg. Med. Chem. Lett.* 2009, 19, 5095–5100. [CrossRef]

33. Tuzimski, T.; Sztanke, K. Retention data for some carbonyl derivatives of imidazo[2,1-c][1,2,4]triazine in reversed-phase systems in TLC and HPLC and their use for determination of lipophilicity. Part 1. Lipophilicity of 8-aryl-3-phenyl-6,7-dihydro-4H-imidazo[2,1-c][1,2,4]triazine-4-ones and Methods for their Manufacture. *J. Planar Chromatogr.* 2005, 18, 274–281.

34. Łyszczek, R.; Bartyzel, A.; Głuchowska, H.; Mazur, L.; Sztanke, M.; Sztanke, K. Thermal investigations of biologically important fused azaisocytosine-containing congeners and the crystal structure of one representative. *J. Anal. Appl. Pyrolysis* 2018, 135, 141–151. [CrossRef]

35. Abraham, M.H.; Ibrahim, A.; Zissimos, A.M. Determination of sets of solute descriptors from chromatographic measurements. *J. Chromatogr. A* 2004, 1037, 29–47. [CrossRef] [PubMed]

36. Abraham, M.H. The factors that influence permeation across the blood-brain barrier. *Eur. J. Med. Chem.* 2004, 39, 235–240. [CrossRef] [PubMed]

37. Abraham, M.H.; Ibrahim, A.; Zissimos, A.M. Determination of sets of solute descriptors from chromatographic measurements. *J. Chromatogr. A* 2004, 1037, 29–47. [CrossRef] [PubMed]

38. Abraham, M.H.; Chadha, H.S.; Mitchell, R.C. Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. *J. Pharm. Sci.* 1994, 83, 1257–1268. [CrossRef]

39. Abraham, M.H. Scales of Solute Hydrogen-bonding: Their Construction and Application to Physicochemical and Biochemical Processes. *Chem. Soc. Rev.* 1993, 22, 73–83. [CrossRef]

40. Abraham, M.H.; Zissimos, A.M. Determination of sets of solute descriptors from chromatographic measurements. *J. Chromatogr. A* 2004, 1037, 29–47. [CrossRef] [PubMed]

41. Abraham, M.H. The factors that influence permeation across the blood-brain barrier. *Eur. J. Med. Chem.* 2004, 39, 235–240. [CrossRef] [PubMed]

42. Vitha, M.; Carr, P.W. The chemical interpretation and practice of linear solvation energy relationships in chromatography. *J. Chromatogr. A* 2006, 1126, 143–194. [CrossRef] [PubMed]

43. Mente, S.R.; Lombardo, F. A recursive-partitioning model for blood-brain barrier permeation. *J. Comp. Aided Mol. Design.* 2005, 19, 465–481. [CrossRef]

44. Bujak, R.; Struck-Lewicka, W.; Kaliszian, M.; Kaliszian, R.; Markuszewski, M.J. Blood-brain barrier permeability mechanisms in view of quantitative structure-activity relationships (QSAR). *J. Pharm. Biomed. Anal.* 2015, 108, 29–37. [CrossRef]
45. Carpenter, T.S.; Kirshner, E.D.A.; Lau, Y.; Wong, S.E.; Nilmeyer, J.P.; Lightstone, F.C. A Method to Predict Blood-Brain Barrier Permeability of Drug-Like Compounds Using Molecular Dynamics Simulations. *Biophys. J.* 2014, 107, 630–641. [CrossRef]

46. Chen, Y.; Zhu, Q.-J.; Pan, J.; Wu, X.-P. A prediction model for blood-brain barrier permeation and analysis on its parameter biologically. *Comp. Meth. Prog. Biomed.* 2009, 95, 280–287. [CrossRef] [PubMed]

47. Ooms, F.; Weber, T.; Currup, P.A.; Testa, B. A simple model to predict blood-brain barrier permeation from 3D molecular fields. *Biochim. Biophys. Acta* 2002, 1587, 118–125. [CrossRef]

48. Sagandykova, G.N.; Pomastowski, P.P.; Kaliszan, R.; Buszewski, B. Modern analytical methods for consideration of natural biological activity. *Trends Anal. Chem.* 2018, 109, 198–213. [CrossRef]

49. Kaliszan, R.; Markuszewski, M. Brain/blood distribution described by a combination of partition coefficient and molecular mass. *Int. J. Pharm.* 1996, 145, 9–16. [CrossRef]

50. Österberg, T.; Norinder, U. Prediction of polar surface area and drug transport processes using simple parameters and PLS statistics. *J. Chem. Inf. Comput. Sci.* 2000, 40, 1408–1411. [CrossRef] [PubMed]

51. Clark, D.E. Rapid calculation of polar molecular surface area and its application to the prediction of drug transport properties. 2. Prediction of blood-brain barrier penetration. *J. Pharm. Sci.* 1999, 88, 815–821. [CrossRef] [PubMed]

52. Norinder, U.; Haebelin, M. Computational approaches to the prediction of the blood-brain distribution. *Adv. Drug Deliv. Rev.* 2002, 54, 291–313. [CrossRef]

53. Luco, J.M. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling. *J. Chem. Inf. Comput. Sci.* 1999, 39, 396–404. [CrossRef]

54. Feher, M.; Sourial, E.; Schmidt, J.M. A simple model for the prediction of blood-brain partitioning. *Int. J. Pharm.* 2000, 201, 239–247. [CrossRef]

55. Fu, X.-C.; Song, Z.-F.; Fu, C.-Y.; Liang, W.-Q. A simple predictive model for blood-brain barrier penetration. *Pharmacazie* 2005, 60, 354–358.

56. Fu, X.-C.; Wang, G.-P.; Shan, H.-L.; Liang, W.-Q.; Gao, J.-Q. Predicting blood-brain barrier penetration from molecular weight and number of polar atoms. *Eur. J. Pharm. Biopharm.* 2008, 70, 462–466. [CrossRef]

57. Young, R.C.; Mitchell, R.C.; Brown, T.H.; Ganellin, C.R.; Griffiths, R.; Jones, M.; Rana, K.K.; Saunders, D.; Smith, I.R.; Sore, N.E.; et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. *J. Med. Chem.* 1988, 31, 656–671. [CrossRef]

58. van de Waterbeemd, H.; Kansy, M. Hydrogen-bonding capacity and brain penetration. *Chemia* 1992, 46, 299–303.

59. Lombardo, F.; Blacke, J.F.; Curatolo, W.J. Computation of brain-blood partitioning of organic solutes via free energy calculations. *J. Med. Chem.* 1996, 39, 4750–4755. [CrossRef] [PubMed]

60. Kelder, J.; Grootenhuis, P.D.J.; Bayada, D.M.; Delbressine, L.P.C.; Ploemen, J.P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. *Pharm. Res.* 1999, 16, 1514–1519. [CrossRef] [PubMed]

61. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. *J. Med. Chem.* 2000, 43, 3714–3717. [CrossRef] [PubMed]

62. Vilars, S.; Chakrabarti, S.; Constanzi, S. Prediction of passive blood-brain partitioning: Straightforward and effective classification models based on in silico derived physicochemical descriptors. *J. Mol. Graph. Model.* 2010, 28, 899–903. [CrossRef] [PubMed]

63. Raevsky, O.A.; Solodova, S.L.; Raevskaya, O.E.; Mannhold, R. Molecular biology problems of drug design and mechanism of drug action. Quantitative interactions between the structures of organic compounds and their abilities to penetrate the blood-brain barrier. *Pharm. Chem. J.* 2012, 46, 133–138. [CrossRef]

64. Ruiz-Ángel, M.J.; García-Álvarez-Coque, M.C.; Berthod, A. New insights and recent developments in micellar liquid chromatography (review). *Sep. Purif. Res.* 2009, 38, 45–96. [CrossRef]

65. Mensch, J.; Oyarzabal, J.; Mackie, C.; Augustijns, P. In vitro, in vitro and in silico methods for small molecule transfer across the BBB. *J. Pharm. Sci.* 2009, 98, 4429–4468. [CrossRef]

66. Naik, P.; Cucullo, L. In vitro blood-brain barrier models: Current and perspective technologies. *J. Pharm. Sci.* 2012, 101, 1337–1354. [CrossRef]
67. Tetko, I.V.; Tanchuk, V.Y. Application of associative neural networks for prediction of lipophilicity in ALOGPS 2.1 program. J. Chem. Inf. Comput. Sci. 2002, 42, 1136–1145. [CrossRef]

68. Tetko, I.V.; Tanchuk, V.Y.; Villa, A.E. Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J. Chem. Inf. Comput. Sci. 2001, 41, 1407–1421. [CrossRef]

**Sample Availability:** Samples of the compounds 1–65 are available from the authors.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).